We established the Drug Advisory Committee in 2007 to provide us with advice on drugs and the medical conditions/criteria for coverage. The Drug Advisory provides recommendations by considering what a drug is used for, its benefits, value and safety.
The Drug Advisory Committee makes evidence-based recommendations to help us decide on the specific drugs to be included in the WSIB Drug Benefit Plan.
The committee brings together people with expertise from different disciplines in medicine, pharmacy, epidemiology, and pharmacoeconomics and includes a member of the public.
Read the Drug Advisory Committee Terms of Reference (PDF).
Paul Oh, MD, FRCP(C) (Chair)
Medical Director, Cardiovascular Prevention and Rehabilitation Program, Toronto Rehabilitation Institute, University Health Network
Associate Professor, Pharmacology and Toxicology, Department of Medicine, University of Toronto
Mario Bédard, BScPharm, PharmD, RPh (Vice Chair)
Director, Pharmacy, The Ottawa Hospital
Treasurer, Executive Committee, Canadian Society of Hospital Pharmacists
Sandeep Kakan, MBA (Public Member)
National Representative, Pensions and Benefits, Unifor
Lisa Burry, PharmD
Clinician Scientist and Clinical Pharmacy Specialist, Lunenfeld-Tanenbaum Research Institute, Sinai Health System
Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
Andrea Furlan, MD, PhD
Physician and Senior Scientist, Toronto Rehabilitation Institute, University Health Network
Assistant Professor, Division of Physiatry, Department of Medicine, Faculty of Medicine, University of Toronto
Muhammad Mamdani, PharmD, MA, MPH
Director, Li Ka Shing Centre for Healthcare Analytics Research and Training, St. Michael’s Hospital
Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
Senior Adjunct Scientist, Institute for Clinical Evaluative Sciences
Wilfred Steer, BScPharm
Pharmacist, Health Sciences North
Lecturer, Health Sciences, Northern Ontario School of Medicine, Laurentian University